{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:15:06Z","timestamp":1789161306132,"version":"build-2803163510"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011747","name":"Novo Nordisk Foundation Center for Basic Metabolic Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["9039\u201300298B"],"award-info":[{"award-number":["9039\u201300298B"]}],"id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"K\u00f8benhavns Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002808","name":"Carlsbergfondet","doi-asserted-by":"publisher","award":["NNF21OC0070347"],"award-info":[{"award-number":["NNF21OC0070347"]}],"id":[{"id":"10.13039\/501100002808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R242\u20132017-409"],"award-info":[{"award-number":["R242\u20132017-409"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF17SA0031406"],"award-info":[{"award-number":["NNF17SA0031406"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015223","name":"Danish Diabetes Academy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["9065\u201300181B"],"award-info":[{"award-number":["9065\u201300181B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.biopha.2023.114383","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T12:16:35Z","timestamp":1676117795000},"page":"114383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Long-acting agonists of human and rodent GLP-2 receptors for studies of the physiology and pharmacological potential of the GLP-2 system"],"prefix":"10.1016","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6995-7933","authenticated-orcid":false,"given":"Sarina","family":"Gadgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne A.","family":"Windel\u00f8v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sine P.","family":"Schiellerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens J.","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8509-2036","authenticated-orcid":false,"given":"Bolette","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette M.","family":"Rosenkilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.114383_bib1","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1111\/bph.15766","article-title":"Novel agonist and antagonist radioligands for the GLP-2 receptor. Useful tools for studies of basic GLP-2 receptor pharmacology","volume":"179","author":"Gadgaard","year":"2022","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2023.114383_bib2","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1073\/pnas.93.15.7911","article-title":"Induction of intestinal epithelial proliferation by glucagon-like peptide 2","volume":"93","author":"Drucker","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2023.114383_bib3","article-title":"Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2","author":"Drucker","year":"1997","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.biopha.2023.114383_bib4","article-title":"Intestinal growth-promoting properties of glucagon-like peptide-2 in mice","author":"Chun-Hui","year":"1997","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.biopha.2023.114383_bib5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S1091-255X(98)80005-X","article-title":"Glucagon-like peptide 2 is a potent growth factor for small intestine and colon","volume":"2","author":"Litvak","year":"1998","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.biopha.2023.114383_bib6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0022-3468(99)90221-X","article-title":"Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo","volume":"34","author":"Kato","year":"1999","journal-title":"J. Pedia Surg."},{"key":"10.1016\/j.biopha.2023.114383_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2005.10.004","article-title":"Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans","volume":"130","author":"Meier","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2023.114383_bib8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/00365520802538195","article-title":"Glucagon-like peptide-2 increases mesenteric blood flow in humans","volume":"44","author":"Bremholm","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.biopha.2023.114383_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.regpep.2012.11.002","article-title":"Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure","volume":"181","author":"Askov-Hansen","year":"2013","journal-title":"Regul. Pept."},{"key":"10.1016\/j.biopha.2023.114383_bib10","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1359\/jbmr.2003.18.12.2180","article-title":"Role of Gastrointestinal Hormones in Postprandial Reduction of Bone Resorption","volume":"18","author":"Henriksen","year":"2003","journal-title":"J. Bone Min. Res"},{"key":"10.1016\/j.biopha.2023.114383_bib11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bone.2003.09.009","article-title":"Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2","volume":"34","author":"Henriksen","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2023.114383_bib12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bone.2019.05.014","article-title":"GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men","volume":"125","author":"Skov-Jeppesen","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2023.114383_bib13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/00365520801965381","article-title":"Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract","volume":"43","author":"Gottschalck","year":"2008","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.biopha.2023.114383_bib14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bone.2006.09.025","article-title":"Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women","volume":"40","author":"Henriksen","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2023.114383_bib15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bone.2009.07.008","article-title":"Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD","volume":"45","author":"Henriksen","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2023.114383_bib16","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1073\/pnas.211278098","article-title":"Modulation of specific intestinal epithelial progenitors by enteric neurons","volume":"98","author":"Bjerknes","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2023.114383_bib17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1152\/ajpgi.00389.2012","article-title":"Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration","volume":"307","author":"El-Jamal","year":"2014","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.biopha.2023.114383_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.regpep.2004.07.009","article-title":"GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors","volume":"124","author":"\u00d8rskov","year":"2005","journal-title":"Regul. Pept."},{"key":"10.1016\/j.biopha.2023.114383_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.peptides.2015.02.007","article-title":"The glucagon-like peptide 2 receptor is expressed in enteric neurons and not in the epithelium of the intestine","volume":"67","author":"Pedersen","year":"2015","journal-title":"Pept. (NY)"},{"key":"10.1016\/j.biopha.2023.114383_bib20","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1053\/gast.2000.16489","article-title":"Enteroendocrine localization of GLP-2 receptor expression in humans and rodents","volume":"119","author":"Yusta","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2023.114383_bib21","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1210\/en.2019-00398","article-title":"Localization of Glucagon-Like Peptide-2 Receptor Expression in the Mouse","volume":"160","author":"Yusta","year":"2019","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2023.114383_bib22","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s00125-007-0761-6","article-title":"The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas","volume":"50","author":"de Heer","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2023.114383_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6793-11-12","article-title":"Receptors and effects of gut hormones in three osteoblastic cell lines","volume":"11","author":"Pacheco-Pantoja","year":"2011","journal-title":"BMC Physiol."},{"key":"10.1016\/j.biopha.2023.114383_bib24","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/jbmr.4308","article-title":"The Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidism\u2014A Randomized Crossover Study","volume":"36","author":"Skov-Jeppesen","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.biopha.2023.114383_bib25","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1124\/mol.63.6.1256","article-title":"The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints","volume":"63","author":"Fredriksson","year":"2003","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2023.114383_bib26","doi-asserted-by":"crossref","unstructured":"Gabe M.B.N., Rosenkilde M.M., Osborne H.B. (2020) Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [ E354Q] facilitate receptor desensitization and long \u2010 term impairment of the GIP system. 126:122\u2013132.","DOI":"10.1111\/bcpt.13289"},{"key":"10.1016\/j.biopha.2023.114383_bib27","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1021\/acsptsci.0c00193","article-title":"GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats","volume":"4","author":"van der Velden","year":"2021","journal-title":"ACS Pharm. Transl. Sci."},{"key":"10.1016\/j.biopha.2023.114383_bib28","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41586-018-0535-y","article-title":"Cryo-EM structure of the active, G s -protein complexed, human CGRP receptor","volume":"561","author":"Liang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.114383_bib29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.febslet.2010.12.011","article-title":"Conformational and molecular interaction studies of glucagon-like peptide-2 with its N-terminal extracellular receptor domain","volume":"585","author":"Venneti","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2023.114383_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature22394","article-title":"Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein","volume":"546","author":"Zhang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.114383_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.str.2021.04.001","article-title":"Investigating GIPR (ant)agonism: A structural analysis of GIP and its receptor","author":"Smit","year":"2021","journal-title":"Structure"},{"key":"10.1016\/j.biopha.2023.114383_bib32","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/s41422-020-00442-0","article-title":"A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor","volume":"30","author":"Sun","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.biopha.2023.114383_bib33","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.2000.278.1.E134","article-title":"Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats","author":"Tavares","year":"2000","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2023.114383_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-0115(01)00316-0","article-title":"The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist","volume":"103","author":"Thulesen","year":"2002","journal-title":"Regul. Pept."},{"key":"10.1016\/j.biopha.2023.114383_bib35","doi-asserted-by":"crossref","unstructured":"Christensen P., Chavda V.P., Ajabiya J., Teli D., Bojarska J., Apostolopoulos V. (2022) molecules Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. https:\/\/doi.org\/10.3390\/molecules27134315.","DOI":"10.3390\/molecules27134315"},{"key":"10.1016\/j.biopha.2023.114383_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials","author":"Gilbert","year":"2020","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.biopha.2023.114383_bib37","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1177\/0091270008320605","article-title":"Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects","volume":"48","author":"Marier","year":"2008","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2023.114383_bib38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/jpet.119.262238","article-title":"Pharmacological characterization of apraglutide, a novel long-acting peptidic glucagon-like peptide-2 agonist, for the treatment of short bowel syndrome","volume":"373","author":"Hargrove","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2023.114383_bib39","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.3748\/wjg.v28.i44.6258","article-title":"Glucagon-like peptide-2 analogues for Crohn\u2019s disease patients with short bowel syndrome and intestinal failure","volume":"28","author":"Pizzoferrato","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2023.114383_bib40","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1021\/acs.jmedchem.7b00768","article-title":"Stapled, Long-Acting Glucagon-like Peptide 2 Analog with Efficacy in Dextran Sodium Sulfate Induced Mouse Colitis Models","volume":"61","author":"Yang","year":"2018","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2023.114383_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.peptides.2013.11.012","article-title":"Purified PEGylated porcine glucagon-like peptide-2 reduces the severity of colonic injury in a murine model of experimental colitis","volume":"52","author":"Qi","year":"2014","journal-title":"Pept. (NY)"},{"key":"10.1016\/j.biopha.2023.114383_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050630","article-title":"GLP2\u20132\u2009G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn\u2019s Disease Model","author":"Alters","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114383_bib43","doi-asserted-by":"crossref","unstructured":"Hytting-Andreasen R., Balk-M\u00f8ller E., Hartmann B., Pedersen J., Windel\u00f8v J.A., Holst J.J., Kissow H. (2018) Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice. https:\/\/doi.org\/10.1371\/journal.pone.0198046.","DOI":"10.1371\/journal.pone.0198046"},{"key":"10.1016\/j.biopha.2023.114383_bib44","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1210\/en.2003-0801","article-title":"Impaired Intestinal Proglucagon Processing in Mice Lacking Prohormone Convertase 1","volume":"145","author":"Ugleholdt","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2023.114383_bib45","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bcp.2017.02.012","article-title":"GIP(3\u201330)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release","volume":"131","author":"Sparre-Ulrich","year":"2017","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.biopha.2023.114383_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106058","article-title":"GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment","volume":"176","author":"Gabe","year":"2022","journal-title":"Pharm. Res"},{"key":"10.1016\/j.biopha.2023.114383_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/bph.16040","article-title":"Biased GLP-2 agonist with strong G protein-coupling but impaired arrestin recruitment and receptor desentization enhances intestinal growth in mice","author":"Gabe","year":"2023","journal-title":"Br J Pharmacology"},{"key":"10.1016\/j.biopha.2023.114383_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/bph.15866","article-title":"N-terminal alterations turn the gut hormone GLP-2 into an antagonist with gradual loss of GLP-2 receptor selectivity towards more GLP-1 receptor interaction","author":"Gabe","year":"2022","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2023.114383_bib49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.biopha.2023.114383_bib50","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1080\/00365520802200028","article-title":"Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome","volume":"43","author":"Gottschalck","year":"2008","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.biopha.2023.114383_bib51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.lfs.2019.04.013","article-title":"Glucagon like peptide 2 has a positive impact on osteoporosis in ovariectomized rats","volume":"226","author":"Xu","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2023.114383_bib52","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2023.114383_bib53","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114383_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03941-2","article-title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","author":"Jones","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.114383_bib55","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2023.114383_bib56","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2023.114383_bib57","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1210\/jc.2013-3766","article-title":"A Functional Amico Acid Substitution in the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Gene is Assocaited With Lower Bone Mineral Denisty and Increased Fracture Risk","volume":"4","author":"Torekov","year":"2014","journal-title":"JCEM"},{"key":"10.1016\/j.biopha.2023.114383_bib58","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bph.13323","article-title":"Species-specific action of (Pro3)GIP \u2013 a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors","volume":"173","author":"Sparre-Ulrich","year":"2016","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2023.114383_bib59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bcp.2018.01.040","article-title":"Human GIP(3-30)NH 2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors","volume":"150","author":"Gabe","year":"2018","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.biopha.2023.114383_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-019-1976-2","article-title":"Animal to human translation: A systematic scoping review of reported concordance rates","volume":"17","author":"Leenaars","year":"2019","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.biopha.2023.114383_bib61","article-title":"GLP-2 administration in ovariectomized mice enhances collagen maturity but did not improve bone strength","volume":"12","author":"Gobron","year":"2020","journal-title":"Bone Rep."},{"key":"10.1016\/j.biopha.2023.114383_bib62","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1124\/jpet.107.120006","article-title":"Oxyntomodulin differentially affects glucagon-like peptide-1 receptor \u03b2-arrestin recruitment and signaling through G\u03b1s","volume":"322","author":"Jorgensen","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2023.114383_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2018.10.018","article-title":"Insulin Secretion Depends on Intra-islet Glucagon Signaling","author":"Svendsen","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2023.114383_bib64","doi-asserted-by":"crossref","first-page":"8888","DOI":"10.1021\/bi000497p","article-title":"Structural determinants for activity of glucagon-like peptide-2","volume":"39","author":"DaCambra","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2023.114383_bib65","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2220\/biomedres.34.129","article-title":"A novel truncated glucagon-like peptide 2 (GLP-2) as a tool for analyzing GLP-2 receptor agonists","volume":"34","author":"Yamazaki","year":"2013","journal-title":"Biomed. Res. (Jpn. )"},{"key":"10.1016\/j.biopha.2023.114383_bib66","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/bph.13384","article-title":"N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor","volume":"173","author":"Hansen","year":"2016","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2023.114383_bib67","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1021\/acs.jmedchem.5b01909","article-title":"Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance","volume":"59","author":"Wi\u015bniewski","year":"2016","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2023.114383_bib68","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1053\/gast.2001.22555","article-title":"Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon","volume":"120","author":"Jeppesen","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2023.114383_bib69","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/003655202317316006","article-title":"Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon","volume":"37","author":"Haderslev","year":"2002","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.biopha.2023.114383_bib70","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1146\/annurev-physiol-021113-170317","article-title":"Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2","volume":"76","author":"Drucker","year":"2014","journal-title":"Annu Rev. Physiol."},{"key":"10.1016\/j.biopha.2023.114383_bib71","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40262-013-0079-0","article-title":"Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides","volume":"52","author":"Diao","year":"2013","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.biopha.2023.114383_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109939","article-title":"Acylation of Glucagon-like peptide-2: interaction with lipid membranes and in vitro intestinal permeability","author":"Trier","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114383_bib73","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.bjp.0705397","article-title":"GLP-1 derivative liraglutide in rats with \u03b2-cell deficiencies: Influence of metabolic state on \u03b2-cell mass dynamics","volume":"140","author":"Sturis","year":"2003","journal-title":"Br. J. Pharm."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223001713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223001713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:48:52Z","timestamp":1776772132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223001713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":73,"alternative-id":["S0753332223001713"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114383","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-acting agonists of human and rodent GLP-2 receptors for studies of the physiology and pharmacological potential of the GLP-2 system","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114383"}}